炎症性肠病患者与代谢综合征的相关性分析

目的 探索炎症性肠病(inflammatory bowel disease, IBD)和代谢综合征(metabolic syndrome, MS)之间的相关性。方法 选取2020年1月至2023年8月就诊于新疆维吾尔自治区人民医院的97例溃疡性结肠炎(ulcerative colitis, UC)患者和63例克罗恩病(crohn′s disease, CD)患者为病例组,同期来院体检的健康体检者320例为对照组。收集所有研究对象的一般情况和相关检验及检查结果。整理资料,计算体重指数(body mass index, BMI)及MS组分个数,统计代谢相关性脂肪性肝病(metabolic associated fatty liver disease, MAFLD)和MS的发病情况,并分析UC、CD患者同上述一般因素及MS相关指标水平之间的关系。结果 UC组和CD组患者合并高血压、糖尿病及MAFLD的比率均显著高于对照组(P<0.05)。多因素Logistic回归分析显示,MS相关指标水平与IBD之间存在一定程度的相关性。具体来说,高血压史、糖尿病史、甘油三酯、高密度脂蛋白、低密度脂蛋...     

炎症性肠病患者肠黏膜炎症和非炎症组织CD27的激活表达

目的比较炎症性肠病患者肠黏膜炎症组织、非炎症组织及正常对照者肠黏膜CD27激活表达的差异,探讨CD27激活表达在炎症性肠病发病中的意义。方法共纳入32例克罗恩病患者、41例溃疡性结肠炎患者及40例正常对照者。分别应用West-ern blot试验和SYBR-green real time PCR方法分析炎症性肠病患者肠黏膜炎症组织、非炎症组织及正常对照者肠黏膜CD27蛋白及其mRNA的表达。数据处理使用GraphPad Prism 5软件。结果克罗恩病和溃疡性结肠炎患者肠黏膜炎症组织CD27蛋白及其mRNA表达均显著高于非炎症组织及正常对照组织(P均0.01);克罗恩病患者肠黏膜非炎症组织CD27蛋白及其mRNA表达显著高于正常对照组织(P=0.000);溃疡性结肠炎患者肠黏膜非炎症组织CD27蛋白表达显著高于正常对照组织(P=0.000)。结论炎症性肠病患者肠黏膜组织中存在CD27的激活表达,这种激活效应不仅出现在内镜表现为炎症性肠病的炎症组织中,甚至出现在炎症性肠病患者内镜表现为正常的肠黏膜中,CD27的激活表达是炎症性肠病发病的早期事件。     

炎症性肠病患者中医舌象特征分析

目的:探讨炎症性肠病患者中医舌象特征,为中医药治疗炎症性肠病提供参考依据。方法:纳入广州中医药大学第二附属医院2022年3-12月行结直肠镜检查的27例炎症性肠病患者(炎症性肠病组)及同期25例健康人(正常对照组)为研究对象,采集舌象,并分析其在分布上的差异。结果:炎症性肠病组和正常对照组在舌色及苔色的比较上,差异无统计学意义(P>0.05)。炎症性肠病组患者正常舌形的占比低于正常对照组,差异有统计学意义(P<0.05),齿痕舌、腻苔的占比显著高于正常对照组,差异有统计学意义(P<0.05)。亚组分析中,溃疡性结肠炎组和克罗恩病组在舌象的比较上,差异无统计学意义(P>0.05)。结论:炎症性肠病患者的舌象多见齿痕、腻苔,这些特征与脾虚、湿盛有一定的关系。     

炎症性肠病患者服用铁剂的耐受性及疗效

目的 回顾性地比较炎症性肠病（IBD）患者与非IBD患者服用铁剂的耐受性与疗效.方法 对2000年1月至2005年3月期间住院病历中符合IBD的217例患者及26例非炎症性原因引起缺铁的患者进行回顾性分析.结果 217例IBD患者中有42例（19.4%）,非IBD组有15例（57.7%）患者接受过口服铁剂治疗,IBD组有7例（16.7%）,非IBD组有3例（11.5%）不能耐受口服铁剂治疗（P＞0.05）.依据检查结果,IBD组有11例（31.4%）,非IBD组有8例（38.1%）治疗有效.结论 IBD患者对口服铁剂的耐受性和治疗效果与非IBD患者相比,没有明显差异.     

炎症性肠病结肠镜检查的评价

随着结肠镜对炎症性肠病镜下和活检病理形态改变的认识不断加深 ,它的使用价值也不断提高。Ｆｒ櫣ｈｍｏｒｇｅｎ总结过去 10年经验 ,发现对溃疡性结肠炎确诊率达 93.9% ,对克罗恩病达 77.3%。因此 ,近年来有倾向 ,结肠镜应列为诊断炎症性肠病的常规检查。结合我院过去 2 0年中炎症性肠病所见的形态改变 ,对其使用价值进行讨论。　　炎症性肠病在结肠镜下的形态 ,首先表现为分布方式和累及部位不同。溃疡性结肠炎呈连续性分布 ,并且疾病初期往往先累及直肠 ,逐渐向近端结肠蔓延 ,严重者累及整个结肠 ,仅有极少数倒灌性肠炎者可达回肠末端近…     

炎症性肠病的肠外表现和并发症

<正>克罗恩病(CD)和溃疡性结肠炎(UC)都属于炎症性肠病(IBD)。IBD肠外表现的病因可能涉及到多种因素,有时候IBD的肠外表现(IBD本身累及其他器官)与IBD继发的肠外并发症(如营养不良、慢性炎症、药物的不良反应等所致)比较难鉴别。一般而言,IBD的肠外表现与IBD的活动性一致,但有些可能与IBD的活动性不一样,例如原发性硬化性胆管炎和强直性脊柱炎。这些肠外表现的症状可     

炎症性肠病合并高血糖症的临床研究

[目的]探讨炎症性肠病(IBD)合并高血糖症的临床特点及危险因素.[方法]以合并高血糖症的IBD患者73例为观察组,按照1:1比例选取年龄、性别与观察组一致的无高血糖症的IBD患者73例为对照组,比较2组患者临床特点的差异,并分析IBD患者发生高血糖的危险因素.[结果]与对照组相比,观察组的凝血功能指标:凝血酶原时间活...     

儿童炎症性肠病的临床表现和疾病表型

<正>儿童炎症性肠病(PIBD)分为溃疡性结肠炎(UC)、克罗恩病(CD)和炎症性肠病未定型(IBDU)3种。UC通常是累及直肠表面的炎症,并以连续方式延伸至邻近黏膜,CD的特点是透壁性炎症累及胃肠道的任何部位。IBDU是局限在结肠黏膜的炎症,其组织学特征在UC和CD之间无法区分[1]。PIBD因其发病机制复杂、临床表现多样且不典型     

炎症性肠病患者的肠外表现(附201例临床分析)

目的了解炎症性肠病(IBD)患者肠外表现的发生情况。方法对1978-01~2003-12期间北京大学第一医院收治的201例IBD患者的临床资料进行回顾性分析。结果25年间共收治IBD患者201例,其中溃疡性结肠炎(UC)患者182例,克罗恩病(CD)患者19例。IBD伴肠外表现发生率为20·9%(42/201),UC患者为21·43%(39/182),CD患者为15·79%(3/19)。女性显著多于男性(P<0·05)。UC患者年龄小于20岁者肠外表现发生率高(P<0·01),年龄大于50岁者肠外表现发生率低(P<0·01)。发生于UC活动期者占89·74%(35/39),而发生在缓解期者仅占10·26%(4/39);CD患者肠外表现均发生在活动期。肠外表现中关节、肌肉损害最为多见,其次为皮肤损害。侵犯泌尿系统、甲状腺及肝胆系统者罕见。伴有结节性红斑、坏疽性脓皮病及外周关节炎的患者多易合并其他种肠外表现。结论IBD患者伴有肠外表现者并非少见,女性年轻患者肠外表现发生率高,关节、肌肉及皮肤损害是IBD患者最多见的肠外表现,肠外表现的发生随IBD疾病活动性、疾病严重程度、病变范围的增加有增多的趋势。     

对炎症性肠病诊断治疗规范的建议

炎症性肠病是一种病因尚不十分清楚的慢性非特异性肠道炎症性疾病 ,包括溃疡性结肠炎 (ＵＣ)和克罗恩病 (ＣＤ)。前者是一种慢性非特异性的结肠炎症 ,重者发生溃疡。病变主要累及结肠黏膜和黏膜下层。范围多自远段结肠开始 ,可逆行向近段发展 ,甚至累及全结肠及末段回肠 ,呈连续性分布。临床主要表现为腹泻、腹痛、黏液脓血便。后者病变可累及胃肠道各部位 ,而以末段回肠及其邻近结肠为主 ,为一种慢性肉芽肿性炎症 ,多呈节段性、非对称性分布。临床主要表现为腹痛、腹泻、瘘管、肛门病变和不同程度的全身症状。中华医学会消化病学分会曾先后…     

Approaches to improve quality of care in inflammatory bowel diseases

Studies across medical disciplines have shown gaps in the care recommended in evidence based guidelines and the care actually delivered. Quality improvement projects using systematic audit and feedback interventions such as quality measures, will become increasingly important tools to address these gaps in care. These gaps are also apparent in the care of patients with inflammatory bowel disease. Multiple organizations, including the American Gastroenterology Association and the Crohn’s and Colitis Foundation of America, have developed programs designed to implement quality measures to improve the care of inflammatory bowel disease (IBD) patients. Early results show promise of improving quality, but numerous barriers remain. Gastroenterologists need to be aware of these processes to provide the highest care possible to patients with IBD. We review the existing literature on approaches to quality improvement and their potential application and barriers when applied to IBD care.     

炎症性肠病患者健康相关生活质量评价研究

目的 研究炎症性肠病(IBD)患者的健康相关生活质量(HRQoL)及其影响因素.方法 应用中文版IBD问卷(C-IBDQ),对IBD患者进行横断面调查,评价其HRQoL;通过相关分析和多元线性回归分析,筛选出影响IBD患者HRQoL的主要因素.结果 100例IBD患者(UC 80例,CD 17例,未分型3例)完成问卷,HRQoL总分为(175.9±37.9)分,各维度评分均有下降,其中情感功能受损最为明显;UC患者与CD患者HRQoL总分差异无统计学意义(P＞0.05).活动期IBD患者的HRQoL总分及各维度评分均明显低于缓解期患者(158.7±41.4比186.6±35.1;t=2.813,P=0.006);病程＜1年的患者HRQoL明显低于病程1年以上的患者(P＜0.05);重型IBD患者的HRQoL明显低于轻型患者(P＜0.05);医疗费用主要由个人支付的患者HRQoL较费用大部分由医保支付的患者低,两者在社会功能及经济负担维度差异有统计学意义(P＜0.05).多元线性回归分析提示,对IBD患者HRQoL有影响的因素为病情、疾病活动度、病程、付费方式等.结论 IBD患者HRQoL均有不同程度受损;影响IBD患者HRQoL的因素有病情、疾病活动度、病程、付费方式等;经济负担对IBD患者HRQoL有明显影响.     

Frequency and associated factors of hair loss among patients with inflammatory bowel disease

AIM: To identify the frequency of hair loss among patients with inflammatory bowel disease(IBD) and associated clinical and disease related factors.METHODS: We performed a cross sectional study in a tertiary referral adult IBD clinic.Self-reported history and characteristics of hair loss as well as clinical and demographic information were collected.Data were analyzed using univariate and multivariate analyses.RESULTS: Two hundred and ten consecutive IBD patients were recruited; one hundred and fifty patients met predefined inclusion and exclusion criteria.Thirtythree percent of patients reported a history of hair loss.Age,gender,IBD type and disease duration were not associated with hair loss.Hair loss was reported less frequently among patients with use of mesalamine(54% vs 73%,P = 0.03) and antitumor necrosis factor medications(anti-TNF)(14% vs 40%,P = 0.001).In multivariate analyses adjusting for gender,IBD type and duration of disease,these associations with mesalamine and anti-TNF remained significant [(adjusted values for mesalamine(OR = 0.43,95%CI: 0.19-0.86) and anti-TNFs(OR = 0.28,95%CI: 0.08-0.98)].CONCLUSION: Hair loss is common among patients with IBD.Mesalamine and anti-TNF medications were associated with lower odds of hair loss.Further studies are required to assess the mechanism of hair loss among patients with IBD.     

Pulmonary manifestations of inflammatory bowel disease

Extraintestinal manifestations of inflammatory bowel disease(IBD) are a systemic illness that may affect up to half of all patients. Among the extraintestinal manifestations of IBD, those involving the lungs are relatively rare and often overlooked. However, there is a wide array of such manifestations, spanning from airway disease to lung parenchymal disease, thromboembolic disease, pleural disease, enteric-pulmonary fistulas, pulmonary function test abnormalities, and adverse drug reactions. The spectrum of IBD manifestations in the chest is broad, and the manifestations may mimic other diseases. Although infrequent, physicians dealing with IBD must be aware of these conditions, which are sometimes life-threatening, to avoid further health impairment of the patients and to alleviate their symptoms by prompt recognition and treatment. Knowledge of these manifestations in conjunction with pertinent clinical data is essential for establishing the correct diagnosis and treatment. The treatment of IBD-related respiratory disorders depends on the specific pattern of involvement, and in most patients, steroids are required in the initial management. Corticosteroids, both systemic and aerosolized, are the mainstay therapeutic approach, while antibiotics must also be administered inthe case of infectious and suppurative processes, whose sequelae sometimes require surgical intervention.     

Quality of life,work productivity impairment and healthcare resources in inflammatory bowel diseases in Brazil

BACKGROUND Inflammatory bowel diseases(IBD) have been associated with a low quality of life(QoL) and a negative impact on work productivity compared to the general population.Information about disease control,patient-reported outcomes(PROs),treatment patterns and use of healthcare resources is relevant to optimizing IBD management.AIM To describe QoL and work productivity and activity impairment(WPAI),treatment patterns and use of healthcare resources among IBD patients in Brazil.METHODS A multicenter cross-sectional study included adult outpatients who were previously diagnosed with moderate to severe Crohn's disease(CD) or ulcerative colitis(UC).At enrolment,active CD and UC were defined as having a Harvey Bradshaw Index≥8 or a CD Activity Index≥220 or calprotectin 200 μg/g or previous colonoscopy results suggestive of inadequate control(per investigator criteria) and a 9-point partial Mayo score≥5,respectively.The PRO assessment included the QoL questionnaires SF-36 and EQ-5 D-5 L,the Inflammatory Bowel Disease Questionnaire(IBDQ),and the WPAI questionnaire.Information about healthcare resources and treatment during the previous 3 years was collected from medical records.Chi-square,Fisher's exact and Student's t-/Mann-Whitney U tests were used to compare PROs,treatment patterns and the use of healthcare resources by disease activity(a=0.05).RESULTS Of the 407 patients in this study(CD/UC:64.9%/35.1%,mean age 42.9/45.9 years,54.2%/56.6% female,38.3%/37.1% employed),44.7%/25.2% presented moderate-to-severe CD/UC activity,respectively,at baseline.Expressed in median values for CD/UC,respectively,the SF-36 physical component was 46.6/44.7 and the mental component was 45.2/44.2,the EQ-visual analog scale score was 80.0/70.0,and the IBDQ overall score was 164.0/165.0.Moderate to severe activity,female gender,being unemployed,a lower educational level and lower income were associated with lower QoL(P 0.05).Median work productivity impairment was 20% and 5% for CD and UC patients,respectively,and activity impairment was 30 %,the latter being higher among patients with moderate to severe disease activity compared to patients with mild or no disease activity(75.0% vs 10.0%,P 0.001).For CD/UC patients,respectively,25.4%/2.8% had at least one surgery,38.3%/19.6% were hospitalized,and 70.7%/77.6% changed IBD treatment at least once during the last 3 years.The most common treatments at baseline were biologics(75.3%)and immunosuppressants(70.9%) for CD patients and 5-AS A compounds(77.5%) for UC patients.CONCLUSION Moderate to severe IBD activity,especially among CD patients,is associated with a substantial impact on QoL,work productivity impairment and an increased number of IBD surgeries and hospitalizations in Brazil.     

Epidemiology and inflammatory bowel diseases

The role of alcohol in causing or aggravating the pathogenesis of inflammatory bowel disease is unclear.For finding a conclusive answer for this valuable question we conducted this review.Only two studies were identified that successfully fulfilled our inclusive criteria.Usual consumption of alcohol reduced the risk compared with less frequent use(odds ratio = 0.57,95%CI:0.37-0.86).Light alcoholic drinking has protective effects against development of ulcerative colitis.But this inverse association disappeared when smoking was included.     

Quality of care delivered to hospitalized inflammatory bowel disease patients

Hospitalized patients with inflammatory bowel disease(IBD)are at high risk for morbidity,mortality,and health care utilization costs.While the literature on trends in hospitalization rates for this disease is conflicting,there does appear to be significant variation in the delivery of care to this complex group,which may be a marker of suboptimal quality of care.There is a need for improvement in identifying patients at risk for hospitalization in an effort to reduce admissions.Moreover,appropriate screening for a number of hospital acquired complications such as venous thromboembolism and Clostridium difficile infection is suboptimal.This review discusses areas of inpatient care for IBD patients that are in need of improvement and outlines a number of potential quality improvement initiatives such as payfor-performance models,quality improvement frameworks,and healthcare information technology.     

Interventions and targets aimed at improving quality in inflammatory bowel disease ambulatory care

Over the past decade,there has been increasing focus on improving the quality of healthcare delivered to patients with chronic diseases,including inflammatory bowel disease.Inflammatory bowel disease is a complex,chronic condition with associated morbidity,health care costs,and reductions in quality of life.The condition is managed primarily in the outpatient setting.The delivery of high quality of care is suboptimal in several ambulatory inflammatory bowel disease domains including objective assessments of disease activity,the use of steroid-sparing agents,screening prior to anti-tumor necrosis factor therapy,and monitoring thiopurine therapy.This review outlines these gaps in performance and provides potential initiatives aimed at improvement including reimbursement programs,quality improvement frameworks,collaborative efforts in quality improvement,and the use of healthcare information technology.     

Elderly patients and inflammatory bowel disease

The incidence and prevalence of inflammatory bowel disease(IBD) is increasing globally. Coupled with an ageing population, the number of older patients with IBD is set to increase. The clinical features and therapeutic options in young and elderly patients are comparable but there are some significant differences. The wide differential diagnosis of IBD in elderly patients may result in a delay in diagnosis. The relative dearth of data specific to elderly IBD patients often resulting from their exclusion from pivotal clinical trials and the lack of consensus guidelines have made clinical decisions somewhat challenging. In addition, age specific concerns such as co-morbidity; locomotor and cognitive function, poly-pharmacy and its consequences need to be taken into account. In applying modern treatment paradigms to the elderly, the clinician must consider the potential for more pronounced adverse effects in this vulnerable group and set appropriate boundaries maximising benefit and minimising harm. Meanwhile, clinicians need to make personalised decisions but as evidence based as possible in the holistic, considered and optimal management of IBD in elderly patients. In this review we will cover the clinical features and therapeutic options of IBD in the elderly; as well as addressing common questions and challenges posed by its management.     

Infertility in men with inflammatory bowel disease

Inflammatory bowel disease(IBD) predominantly affects young adults. Fertility-related issues are therefore im-portant in the m-anagem-ent of patients with IBD. However, relatively m-odest attention has been paid to reproductive issues faced by m-en with IBD. To investigate the effects of IBD and its treatm-ent on m-ale fertility, we reviewed the current literature using a system-atic search for published studies. A PubM ed search were perform-ed using the m-ain search term-s "IBD AND m-ale infertility", "Crohn's disease AND m-ale infertility", "ulcerative colitis AND m-ale infertility". References in review articles were used if relevant. We noted that active inflammation, poor nutrition, alcohol use, sm-oking, m-edications, and surgery m-ay cause infertility in m-en with IBD. In surgery such as proctocolectom-y with ileal pouch-anal anastom-osis, rectal incision seem-s to be associated with sexual dysfunction. Of the m-edications used for IBD, sulfasalazine reversibly reduces m-ale fertility. No other m-edications appear to affect m-ale fertility significantly, although sm-all studies suggested som-e adverse effects. There are lim-ited data on the effects of drugs for IBD on m-ale fertility and pregnancy outcom-es; however, patients should be inform-ed of the possible effects of paternal drug exposure. This review provides inform-ation on fertility-related issues in m-en with IBD and discusses treatm-ent options.